Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 12/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699631 | 0.89 | CHEK1 (0.34) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL5533239 | 0.89 | TTK (0.39) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL3704373 | 0.87 | IRAK4 (0.35) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL3709135 | 0.84 | TTK (0.35) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL3706768 | 0.84 | PSEN1 (0.36) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL3706764 | 0.84 | PSEN1 (0.36) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL3703694 | 0.83 | CHEK1 (0.34) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL3703452 | 0.82 | CHEK1 (0.32) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL3702547 | 0.78 | CHEK1 (0.34) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL3700797 | 0.77 | CHEK1 (0.33) | TTKCCNA2CDK2CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | claimed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | TTK 4669/4885CCNA2 4448/4885CDK2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.